Augmentin SR

Selected form

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal, Bactericidal Broad Spectrum

Treatment option: Bronchitis, Community Acquired Pneumonia, Pneumonia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Augmentin SR

Property	Description
Active ingredient	Amoxicillin and Clavulanic acid
Form	Extended-release tablets (Sustained-Release or SR)
Pharmacological class	beta-Lactam antibiotic and beta-lactamase inhibitor combination
Common use	Counteracting bacterial proliferation in various infections
Origin	Semi-synthetic and derived combination product

The Pharmacological Identity of Augmentin SR

Augmentin SR is classified as a fixed-dose combination product, integrating two primary active substances: the Amoxicillin antibiotic and Clavulanic acid inhibitor. Pharmacologically, this combination is grouped within the beta-lactam antibiotic and beta-lactamase inhibitor class. It is a prescription-only formulation intended to counteract the growth of susceptible bacteria in the body. The strategic combination of these two entities is clinically recognized for improving efficacy against bacteria that have developed resistance to the penicillin class. This combination is noted for its expanded spectrum of activity against certain common pathogens.

Composition and the Sustained-Release (SR) Form

The preparation is delivered via oral administration in an extended-release formulation, commonly referred to by the abbreviation SR (Sustained-Release). The two key active ingredients are Amoxicillin (the antibacterial agent) and Clavulanate potassium (the protective agent). The SR tablet is engineered as a specialized drug delivery system to control the release rate. This mechanism ensures that the therapeutic concentration of both components is maintained steadily over a longer duration, which differentiates it functionally from immediate-release formulations. This distinction in delivery helps ensure continuous exposure of the bacteria to the required therapeutic levels.

General Purpose and Origin

The general purpose of Augmentin SR is to achieve effective bactericidal action against a wide array of susceptible microorganisms, such as those causing typical respiratory or skin infections. Amoxicillin performs the primary function by interfering with the integrity of the bacterial cell wall, while the Clavulanic acid component protects the Amoxicillin from degradation by beta-lactamase enzymes produced by resistant bacteria. This dual-action strategy expands the effective antibacterial spectrum, ensuring the medication remains potent against enzyme-producing strains that would otherwise be unaffected, thereby maximizing its general therapeutic benefit in controlling bacterial proliferation.

What side effects are possible with Augmentin SR?

Possible Side Effects and Safety Information

The safety profile for Augmentin SR (amoxicillin and clavulanate potassium extended-release) is officially categorized by regulatory documents based on frequency and affected body system.

Frequency-Classified Adverse Reactions

Adverse reactions are primarily classified into Common (reported in 1% to 10% of patients) and Uncommon (reported in 0.1% to 1% of patients) categories. The most frequently documented reactions are typically those affecting the Gastrointestinal System.

Classification	Examples of Documented Adverse Reactions
Common	Diarrhea, Nausea, Vaginal mycosis
Uncommon	Dizziness, Headache, Vomiting, Skin rash, Pruritus

Serious Safety Considerations

The combination product is associated with serious, though rare, adverse reactions officially noted in regulatory labeling. These include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Hepatic Dysfunction, including cholestatic jaundice and hepatitis, is also a documented serious risk. Hepatic events may manifest during therapy or several weeks following cessation of therapy.

Population-Specific Restrictions

Official labeling defines specific constraints based on a patient's medical history or physiological status. Augmentin SR is not recommended for use in patients with severe renal impairment (Creatinine Clearance < 30 mL/min) due to the extended-release format. The medicine is also contraindicated in individuals with a history of cholestatic jaundice or hepatic dysfunction previously associated with amoxicillin/clavulanate use.

Overdose and Emergency Response

The official regulatory profile for an overdose of Augmentin SR (Amoxicillin/Clavulanate extended-release) is defined by specific documented clinical manifestations and mandatory emergency actions.

Overexposure is primarily characterized by gastrointestinal symptoms, including severe nausea, vomiting, stomach pain, and diarrhea. Other documented manifestations can involve the central nervous system, such as drowsiness and hyperactivity. Symptoms may also include signs of renal involvement, such as cloudy urine or greatly decreased frequency of urination.

A key severe outcome noted in regulatory labeling is the risk of amoxicillin crystalluria, which may progress to renal failure. Official documents specify that convulsions may occur in patients who have impaired renal function or those receiving high doses, linking population-specific risk directly to drug clearance and toxicity.

In the event of a suspected overdose, regulatory guidance mandates that patients must seek immediate emergency medical attention or contact a Poison Help line immediately. This urgent action is required, especially if the person experiences severe signs such as a seizure, trouble breathing, or collapse. Management procedures described in official labeling include immediate discontinuation of the product, symptomatic treatment, and supportive measures. The combination product can be removed from circulation by hemodialysis.

Therapeutic Uses of Augmentin SR

Augmentin SR (amoxicillin/clavulanate potassium extended-release) is a prescription antibiotic that may be applied in situations involving certain distressing symptoms linked to bacterial infections.

This extended-release formulation is commonly used to help with conditions characterized by periods of heightened symptoms, including community-acquired pneumonia and acute bacterial sinusitis. The medicine is considered relevant for easing symptomatic discomfort in conditions involving the lower respiratory tract and is applicable within clinical settings that involve acute or disruptive symptom patterns.

Targeting Symptom Relief and Stability

This medication supports the management of symptoms related to systemic imbalance, such as discomfort that may become intense or disruptive, especially when discomfort is heightened. It contributes to easing the overall symptom load and may assist in easing discomfort during difficult episodes.

“This medicine is applied across domains where additional symptomatic support is needed, and may contribute to supporting a sense of stability when symptoms are more noticeable.”

Augmentin SR is also applied across condition categories presenting with systemic or localized discomfort. It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations and may assist patients during periods where functional stability is affected.

Quick Fact: Relief for Noticeable Functional Strain

Eligibility and Restrictions for Use

The eligibility for using the extended-release formulation of Amoxicillin/Clavulanate is defined by specific regulatory criteria concerning patient history, age, and organ function.

Contraindications and Restrictions

Classification	Population/Condition
Absolutely Contraindicated	Patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to any beta-lactam antibacterial drugs (penicillins, cephalosporins).
Absolutely Contraindicated	Patients with a previous history of cholestatic jaundice or hepatic dysfunction associated with prior amoxicillin/clavulanate use.
Absolutely Contraindicated	Patients with severe renal impairment (Creatinine Clearance < 30 mL/min) or those on hemodialysis.
Restricted Use	Hepatically impaired patients require caution and regular monitoring of liver function.
Avoided	Patients with suspected infectious mononucleosis are advised to avoid use.

Age and Reproductive Status

The extended-release tablet formulation is generally intended for adults and pediatric patients weighing ge 40 kg. The medicine is not suitable for children below this weight threshold. Use during pregnancy should be avoided unless considered essential by a physician, particularly in the first trimester. The medicine may be administered during lactation.

What should I know about interactions with other medicines?

Augmentin SR Interactions with other medicines and products

This section describes interactions of Augmentin SR (amoxicillin and clavulanate potassium extended-release) documented in government regulatory sources, detailing specific substance combinations and official required constraints.

Interacting Substance/Class	Official Interaction Pattern (Regulatory Outcome)
Probenecid	Co-administration is not recommended. Probenecid decreases the renal tubular secretion of the Amoxicillin component, resulting in increased and prolonged blood concentrations of Amoxicillin.
Oral Anticoagulants (e.g., Warfarin)	Concomitant use may increase the prolongation of prothrombin time (INR), which necessitates monitoring of coagulation parameters.
Oral Contraceptives	Augmentin SR may reduce the efficacy of combined oral contraceptives. The mechanism is stated to involve an effect on intestinal flora leading to lower estrogen reabsorption.
Allopurinol	Concurrent administration increases the incidence of rash in patients receiving both drugs compared to those receiving amoxicillin alone.
Methotrexate	Co-administration may lead to increased serum concentrations of Methotrexate, which is related to competition for renal tubular secretion.

Timing and Administration Constraints

The extended-release formulation is optimally administered at the start of a standardized meal. This procedural constraint is in place to enhance the absorption of the Clavulanate component and to minimize the potential for gastrointestinal intolerance. Taking the medication with a high-fat meal is not recommended, as this is associated with decreased Clavulanate absorption.

Population-Specific Notes

The use of Augmentin SR is formally stated to be avoided in patients with Mononucleosis due to the high risk of a generalized skin rash developing in this patient population.

Mechanism of Action

Augmentin SR functions via a synergistic dual-component pharmacodynamic mechanism targeting bacterial cell wall synthesis and resistance enzymes. The amoxicillin component acts as a beta-lactam antibiotic, selectively binding as an irreversible inhibitor to penicillin-binding proteins (PBPs), which are integral DD-transpeptidases. PBP inhibition prevents the transpeptidation and cross-linking of peptidoglycan monomers, structurally essential for the cellular wall. This molecular pathway interference disrupts cell wall integrity, triggering autolytic enzyme activation and subsequent cellular lysis. The clavulanic acid component, a beta-lactamase inhibitor, functions as a suicide substrate. It covalently and irreversibly binds to the active site of bacterial beta-lactamase enzymes, which are responsible for hydrolyzing the beta-lactam ring of amoxicillin. This inactivation prevents enzymatic degradation of the amoxicillin molecule. The combined action maintains the effective concentration of amoxicillin at its target PBPs, leading to systemic physiological consequences of bacterial structural collapse and destruction.

Dosage and Administration Information

Augmentin SR (amoxicillin and clavulanate potassium) is an extended-release, combination antibiotic and must be used strictly as prescribed by your healthcare provider.

Administration Instructions

Dosage: The recommended adult dosage for conditions like acute bacterial sinusitis and community-acquired pneumonia is typically two Augmentin SR (1000 mg/62.5 mg) tablets taken every 12 hours. The total daily dose is 4,000 mg of amoxicillin and 250 mg of clavulanate. Children weighing 40 kg or more should receive the adult dose.
Timing: Take the tablets at the start of a meal to enhance the absorption of amoxicillin and minimize the potential for gastrointestinal upset. Avoid taking it with a high-fat meal, as this may decrease clavulanate absorption.
Swallowing: Swallow the extended-release tablets whole. Do not crush, chew, or break the tablets unless they have a score line and your doctor instructs you to split them. If splitting is allowed, both halves must be taken immediately.

Important Considerations

Complete the Full Course: Continue taking the medication for the entire prescribed duration, even if your symptoms improve before the treatment is finished. Stopping early or skipping doses may lead to the infection not being fully treated and the development of antibiotic-resistant bacteria.
Missed Dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not take two doses to make up for a missed one.

Recent Clinical Evidence

Augmentin SR: Recent Clinical Evidence

Augmentin SR (amoxicillin/clavulanate extended-release) is an antibiotic combination formulated to provide a sustained profile of amoxicillin in the bloodstream. This extended-release design aims to maintain concentrations of the active antibiotic over the 12-hour dosing interval, which is particularly relevant for activity against certain less-susceptible bacteria.

Clinical Efficacy Research

Clinical trials have primarily evaluated the use of Augmentin SR (typically the 2000 mg/125 mg twice-daily regimen) in adults for the treatment of Acute Bacterial Sinusitis (ABS) and Community-Acquired Pneumonia (CAP).

Research for these indications has generally been conducted as randomized, double-blind, non-inferiority trials. These studies sought to evaluate whether the extended-release formulation was clinically and bacteriologically non-inferior to conventional, immediate-release amoxicillin/clavulanate formulations.

Primary Indication	Key Finding Category (Adults)
Acute Bacterial Sinusitis (ABS)	Clinical and bacteriological success evaluated as comparable to standard regimens.
Community-Acquired Pneumonia (CAP)	Clinical and bacteriological success evaluated as comparable to standard regimens.

Safety Profile and Pharmacokinetics

Pharmacokinetic studies confirm the unique bilayer design provides immediate release of clavulanate (the beta-lactamase inhibitor) and immediate plus sustained release of amoxicillin. This design is intended to extend amoxicillin's activity, which is a concentration- and time-dependent antibiotic.

The overall safety profile in clinical trials for Augmentin SR was generally noted to be similar to that of conventional amoxicillin/clavulanate formulations. Gastrointestinal disturbances, particularly diarrhea, were the most commonly reported adverse events across studies.

Frequently Asked Questions (FAQ)

Common questions about Augmentin SR (FAQ)

Q: What is the main difference between Augmentin SR and regular Augmentin?

The primary difference lies in the extended-release (SR) formulation. Official labeling describes this design as specialized to provide a sustained release of the amoxicillin component over a longer period compared to the immediate-release (regular) formulation. This sustained-release feature differentiates its administration schedule from immediate-release formulations.

Q: Does Augmentin SR treat the same infections as standard Augmentin?

Augmentin SR has specific indications outlined in its regulatory documentation. It is officially indicated only for the treatment of Acute Bacterial Sinusitis (ABS) and Community-Acquired Pneumonia (CAP) caused by susceptible organisms. Other, non-SR formulations of the drug combination may be approved for a broader range of infections.

Q: Can Augmentin SR cause severe stomach problems or diarrhea?

Official safety information lists diarrhea as a Common adverse reaction (occurring in 1% to 10% of patients). Furthermore, all antibiotics in this class carry a documented warning regarding Clostridioides difficile-associated diarrhea (CDAD), which can be a severe form of diarrhea or colitis.

Q: How quickly should I expect Augmentin SR to start working?

The medicine begins working within your body shortly after you take it, as the components are absorbed. However, it is generally noted that it may take a few days before the physical symptoms of the infection begin to show clear signs of improvement. Regulatory documents emphasize the importance of using the medication for the entire prescribed duration for the treatment to be effective.

Q: Is it normal to feel tired or dizzy while taking Augmentin SR?

Official safety data lists dizziness as an Uncommon adverse reaction (occurring in 0.1% to 1% of patients). Fatigue or tiredness is not typically listed among the most common adverse reactions in the product label.

Q: Can I drink alcohol while I am taking Augmentin SR?

Official drug labeling does not list a direct contraindication or specific interaction with alcohol. However, consuming alcohol may potentially increase the likelihood of experiencing certain reported side effects of the medication, such as nausea or dizziness.

Q: Does taking Augmentin SR affect blood tests?

The official product information advises that for administration periods exceeding the typical duration, regular assessment of organ system functions—including hepatic (liver) and hematopoietic (blood) function—may be needed. This advises of the potential for changes in blood counts and liver enzymes that may be observed in blood test results.

Q: Can Augmentin SR cause a metallic or unusual taste in the mouth?

While a specific metallic taste is not always listed as a common reaction, official safety information for amoxicillin/clavulanate has documented reports of a rare side effect called 'black hairy tongue' and other unusual oral symptoms, which suggests the potential for temporary changes in mouth sensations.

Q: Are there any specific dietary restrictions while taking Augmentin SR?

The main specific dietary constraint in the official instructions is that taking the medicine with a high-fat meal is not recommended. This is due to the association with decreased absorption of the clavulanate component.

Q: What is the risk of developing a yeast infection after taking Augmentin SR?

The development of a yeast infection (such as vaginal mycosis or candidiasis) is a documented risk of taking this medicine. It is classified in regulatory documents as a Common adverse reaction, occurring in 1% to 10% of patients, and represents a type of 'superinfection' that can happen with antibiotic use.

Q: Is it possible to be allergic to penicillin but still be able to take Augmentin SR?

Official drug labeling indicates that it is absolutely contraindicated (forbidden) in patients with a history of serious hypersensitivity reactions, like anaphylaxis, to any beta-lactam antibacterial drugs, which include all penicillins. Amoxicillin is a penicillin-class antibiotic.

Q: What is the difference between Amoxicillin/Clavulanate and Augmentin SR?

Amoxicillin/Clavulanate is the generic or chemical name for the combination of the two active drugs. Augmentin SR is the specific brand-name extended-release (SR) formulation of this combination, featuring a specialized design to release the amoxicillin component slowly over 12 hours.

Q: How does the extended-release feature of Augmentin SR work?

The tablet is specially engineered, often using a bilayer design, to manage the release of its two components. This design provides an immediate release of clavulanate and a dual action of immediate and sustained release of amoxicillin. This mechanism helps ensure that therapeutic levels of amoxicillin are maintained throughout the 12-hour dosing interval.

Q: Can Augmentin SR be used for dental infections?

The official indications for the specific extended-release (SR) formulation of Augmentin are limited to Acute Bacterial Sinusitis (ABS) and Community-Acquired Pneumonia (CAP). Although other formulations of the drug combination may be used for other infections, the SR product is not officially indicated for dental infections.

Q: Is Augmentin SR known to cause headaches?

Headache is listed in the official safety information as an Uncommon adverse reaction, which means it has been reported to occur in 0.1% to 1% of patients during clinical studies.

Q: Can I take other antibiotics while on Augmentin SR?

Official drug labeling focuses on interactions with specific non-antibiotic drugs. Co-administration of other antibiotics is a complex clinical decision that is not addressed as a general rule in official patient information.

Q: Does the efficacy of Augmentin SR change if taken at different times of day?

The medicine is designed and directed to be taken consistently every 12 hours to maintain steady, effective therapeutic levels. Taking the medication consistently and at the start of a meal is also specified in regulatory documents to enhance the absorption.

Q: How does the FDA classify the safety of Augmentin SR?

The active components, Amoxicillin/Clavulanate, were classified as Pregnancy Category B under the FDA's former system. This classification generally indicated that animal reproduction studies did not show a risk to the fetus, but there were no adequate and well-controlled studies in pregnant women.

How should Augmentin SR be stored and disposed of?

Storage Requirements

Augmentin SR tablets must be stored at controlled room temperature, specifically between 20^circC and 25^circC (68^circF to 77^circF). The medicine requires protection from moisture and excessive heat to maintain stability.

It is mandatory to keep the tablets in their original container and ensure the container is tightly closed when not in use. Like all medicines, Augmentin SR must be stored out of the sight and reach of children.

Disposal Instructions

Regulatory documents explicitly state that unused or expired Augmentin SR must not be thrown away in household waste or flushed down the toilet or drain. To ensure proper disposal and protect the environment, patients are instructed to consult a pharmacist or use a medicine take-back program for safe pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.